Tiago Cardoso
Overview
Explore the profile of Tiago Cardoso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
652
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kirkeby A, Nelander J, Hoban D, Rogelius N, Bjartmarz H, Storm P, et al.
Cell Stem Cell
. 2023 Oct;
30(10):1299-1314.e9.
PMID: 37802036
Cell replacement therapies for Parkinson's disease (PD) based on transplantation of pluripotent stem cell-derived dopaminergic neurons are now entering clinical trials. Here, we present quality, safety, and efficacy data supporting...
2.
Rajova J, Davidsson M, Avallone M, Hartnor M, Aldrin-Kirk P, Cardoso T, et al.
Mol Ther Methods Clin Dev
. 2023 May;
29:381-394.
PMID: 37251982
Cell therapy for Parkinson's disease has experienced substantial growth in the past decades with several ongoing clinical trials. Despite increasing refinement of differentiation protocols and standardization of the transplanted neural...
3.
Aldrin-Kirk P, Akerblom M, Cardoso T, Nolbrant S, Adler A, Liu X, et al.
Stem Cell Reports
. 2021 Dec;
17(1):159-172.
PMID: 34971563
Transplantation in Parkinson's disease using human embryonic stem cell (hESC)-derived dopaminergic (DA) neurons is a promising future treatment option. However, many of the mechanisms that govern their differentiation, maturation, and...
4.
Tiklova K, Nolbrant S, Fiorenzano A, Bjorklund A, Sharma Y, Heuer A, et al.
Nat Commun
. 2020 Jul;
11(1):3630.
PMID: 32669619
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
5.
Cardoso T, Levesque M
Front Cell Dev Biol
. 2020 Jul;
8:443.
PMID: 32626706
Mesencephalic dopaminergic (mDA) neurons derived from pluripotent stem cells (PSCs) have proven to be pivotal for disease modeling studies and as a source of transplantable tissue for regenerative therapies in...
6.
Hoban D, Shrigley S, Mattsson B, Breger L, Jarl U, Cardoso T, et al.
Proc Natl Acad Sci U S A
. 2020 Jun;
117(26):15209-15220.
PMID: 32541058
Preclinical assessment of the therapeutic potential of dopamine (DA) neuron replacement in Parkinson's disease (PD) has primarily been performed in the 6-hydroxydopamine toxin model. While this is a good model...
7.
Tiklova K, Nolbrant S, Fiorenzano A, Bjorklund A, Sharma Y, Heuer A, et al.
Nat Commun
. 2020 May;
11(1):2434.
PMID: 32415072
Cell replacement is a long-standing and realistic goal for the treatment of Parkinson's disease (PD). Cells for transplantation can be obtained from fetal brain tissue or from stem cells. However,...
8.
Davidsson M, Wang G, Aldrin-Kirk P, Cardoso T, Nolbrant S, Hartnor M, et al.
Proc Natl Acad Sci U S A
. 2019 Dec;
116(52):27053-27062.
PMID: 31818949
Adeno-associated virus (AAV) capsid modification enables the generation of recombinant vectors with tailored properties and tropism. Most approaches to date depend on random screening, enrichment, and serendipity. The approach explored...
9.
Adler A, Cardoso T, Nolbrant S, Mattsson B, Hoban D, Jarl U, et al.
Cell Rep
. 2019 Sep;
28(13):3462-3473.e5.
PMID: 31553914
Cell replacement is currently being explored as a therapeutic approach for neurodegenerative disease. Using stem cells as a source, transplantable progenitors can now be generated under conditions compliant with clinical...
10.
Cardoso T, Adler A, Mattsson B, Hoban D, Nolbrant S, Wahlestedt J, et al.
J Comp Neurol
. 2018 Jul;
526(13):2133-2146.
PMID: 30007046
Dopamine (DA) neurons derived from human embryonic stem cells (hESCs) are a promising unlimited source of cells for cell replacement therapy in Parkinson's disease (PD). A number of studies have...